Why is trib falling

Trinity Biotech's stock decline can be attributed to several factors:

1. Revenue Decline: The company's revenue has fallen by 23% over the past year, which is a significant drop that would naturally concern investors. This decline in revenue is a key reason why the stock's price-to-sales (P/S) ratio is lower than that of other companies in the Medical Equipment industry.
2. FDA Warning Letter: The company's subsidiary Primus Corp received an FDA warning letter after an inspection of its Kansas City Manufacturing facility in January. This could have led to a loss of confidence from investors, as regulatory compliance issues can impact a company's reputation and future business.

In summary, Trinity Biotech's stock decline is likely due to a combination of its poor revenue performance and an FDA warning letter. These factors contribute to the market's perception of the company's risks and potential instability, leading to a lower stock price.